The Institute for Clinical and Economic Review on Tuesday, April 9, released a draft evidence report on the clinical effectiveness and value of DBV Technologies’ Viaskin Peanut and Aimmune Therapeutics’ AR101 for inducing immune tolerance to peanuts.
The report will be open to public comment until 5 p.m. EST May 8, according to a press release.
ICER plans to publish its evidence report May 28. The California Technology Assessment Forum is expected to discuss the report on June 11.
To read the draft evidence report, click here.